KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Current Taxes (2016 - 2025)

Astrazeneca has reported Current Taxes over the past 11 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly results put Current Taxes at $1.1 billion for Q4 2025, down 22.9% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (down 22.9% YoY), and the annual figure for FY2025 was $1.1 billion, down 22.9%.
  • Current Taxes for Q4 2025 was $1.1 billion at Astrazeneca, down from $1.4 billion in the prior quarter.
  • Over the last five years, Current Taxes for AZN hit a ceiling of $1.6 billion in Q4 2023 and a floor of $896.0 million in Q4 2022.
  • Median Current Taxes over the past 5 years was $1.1 billion (2025), compared with a mean of $1.2 billion.
  • Biggest five-year swings in Current Taxes: surged 76.79% in 2023 and later dropped 22.9% in 2025.
  • Astrazeneca's Current Taxes stood at $916.0 million in 2021, then fell by 2.18% to $896.0 million in 2022, then soared by 76.79% to $1.6 billion in 2023, then fell by 11.24% to $1.4 billion in 2024, then dropped by 22.9% to $1.1 billion in 2025.
  • The last three reported values for Current Taxes were $1.1 billion (Q4 2025), $1.4 billion (Q4 2024), and $1.6 billion (Q4 2023) per Business Quant data.